Latest Immunitor Inc. Stories

2014-06-25 23:17:06

Immunitor Inc., reported that company’s first proof-of-concept clinical study of its candidate cancer vaccine in patients with terminal stage of liver cancer has been presented at the immunology conference in Mongolia. Vancouver, British Columbia (PRWEB) June 25, 2014 Immunitor Inc., a Vancouver-based biopharmaceutical company engaged in the discovery and development of oral vaccines, announced today that initial clinical data of the company's lead cancer vaccine has been presented...

2014-04-02 23:32:49

Presentation details three separate tuberculosis immunotherapies developed by Immunitor in collaboration with academic institutions and private companies in Mongolia, China, Thailand, Ukraine, UK, USA and Canada. Data presented support the Immunitor strategy to target inflammation as the main cause of TB and development of immunomodulators and therapeutic vaccines which demonstrate ability to rapidly clear TB, including MDR-TB and TB with HIV. Vancouver, BC, Canada (PRWEB) April 02, 2014...

2013-10-31 23:34:25

Immunitor, Inc., a commercial stage company committed to developing oral therapeutic vaccines, today announced that its second Phase II trial of oral TB vaccine with heat-killed Mycobacterium vaccae (V7) was published in October issue of Immunotherapy journal. Vancouver, BC, Canada (PRWEB) October 31, 2013 This study is second of two Phase II trials run by Immunitor in Ukraine. The trial was conducted in 41 patients with pulmonary tuberculosis randomized into treatment (N=20) and placebo...

Word of the Day
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.